Promethazine Use in Pregnancy
Promethazine is safe and recommended as a first-line antiemetic for nausea and vomiting in pregnancy, with no evidence of increased congenital malformations or adverse pregnancy outcomes. 1
Evidence-Based Recommendation
The 2024 BJOG Green-Top Guideline explicitly recommends antihistamines including promethazine as first-line therapy for nausea and vomiting in pregnancy (NVP) and hyperemesis gravidarum (HG), with Grade A strength based on high-quality evidence 1. This recommendation is supported by Cochrane review data showing no increased risk of congenital malformations or other adverse pregnancy outcomes.
Supporting Safety Data
Human Studies
Large population-based case-control study (22,843 cases): No teratogenic effect identified with oral promethazine use during pregnancy. Initial signals of cleft lip/palate and polydactyly were explained by recall bias and not confirmed with medically-recorded exposures 2
High-dose exposure study: Even in 32 pregnant women who attempted suicide with promethazine (doses 125-1750 mg), no teratogenic or fetotoxic effects were demonstrated, including no impact on cognitive-behavioral development 3
Prospective neurobehavioral study: 143 exposed pregnancies showed no clinically significant adverse neurobehavioral effects on Neonatal Behavioral Assessment Scale or Child Behavior Checklist scores 4
FDA Classification
The FDA labels promethazine as Pregnancy Category C 5. While there are no adequate well-controlled studies in pregnant women, animal studies at therapeutic doses (2.1-4.2 times human doses) showed no teratogenic effects. The label states it "should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus."
Important Clinical Caveats
Timing Considerations
Avoid use within 2 weeks of delivery: Promethazine may inhibit platelet aggregation in the newborn when administered close to delivery 5. This is the primary timing restriction.
Route of Administration
While the guideline and safety data support oral promethazine use, injectable promethazine carries significant risks of tissue necrosis and gangrene unrelated to pregnancy 6, 7. Oral formulation is preferred.
Recent Safety Signal
A 2026 data-mining study identified a potential signal for unspecified hypotension in newborns when promethazine-ondansetron combination was used in the first trimester 8. However, this is hypothesis-generating only and does not contraindicate use, particularly as monotherapy.
Practical Algorithm
For NVP/HG management:
- Start with promethazine (or other H1-antihistamines) as first-line 1
- Use throughout pregnancy except avoid within 2 weeks of expected delivery
- If ineffective, escalate to ondansetron as second-line 1
- Prefer oral over injectable formulations
- Avoid concomitant CNS depressants (reduce doses by 25-50% if necessary) 5
Bottom Line
The convergence of guideline recommendations 1, FDA labeling 5, and multiple human safety studies 4, 2, 3 supports promethazine as an appropriate first-line antiemetic in pregnancy with an established safety profile spanning decades of use.